Biocon Biologics Announces Key Leadership Appointments and Global Talent On-boarding

7 Aug 2023 , 10:03 AM

Biocon Biologics Ltd (BBL), the global biosimilar company and subsidiary of Biocon Ltd, announces significant leadership appointments and onboarding of global talent.

• Rhonda Duffy appointed as Chief Operating Officer (COO), responsible for manufacturing, quality, and supply chain management, with over 30 years of experience in the pharmaceutical industry.
• Dr. Sandeep Athalye promoted to Chief Development Officer, heading CMC, Clinical Development, and Medical and Regulatory Affairs after serving as Chief Medical Officer for six years.
• David Gibson joins as Global Head of Business Development from GlaxoSmithKline (GSK) to lead licensing and strategic partnering activities.
• Stephanie Wasco takes over as Head of Communications – Advanced Markets, driving corporate and marketing communications in regions like the United States and Europe.
• Shreehas Tambe, CEO & Managing Director, Biocon Biologics, expresses confidence in the new leadership team and their contribution to seamless integration of acquired global biosimilar business from Viatris.

BBL has onboarded global talent across multiple functions, including Manufacturing Science and Technology (MSAT), Clinical Development, Finance, HR, Legal, and Compliance.

BBL recently acquired the global biosimilar business of long-standing partner Viatris, with commercial presence in key markets like US, EU, Australia, Canada, and Japan.

Biocon Biologics currently has a robust pipeline of 20 biosimilar assets spanning diabetology, oncology, immunology, and other non-communicable diseases, strengthening its position in the biosimilars industry.

For feedback and suggestions, write to us at [e-mail]